Therapeutic effect of anti-OX40l and anti-TNF-α MAbs in a murine model of chronic colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 284, Issue 4 47-4, 2003, Pages

  Totsuka, T ^a   Kanai, T ^a,c   Uraushihara, K ^a   Iiyama, R ^a   Yamazaki, M ^a   Akiba, H ^b   Yagita, H ^b   Okumura, K ^b   Watanabe, M ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Crohn's disease; OX40L; Therapy; Tumor necrosis factor a

Indexed keywords

CD134 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40L; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CHRONIC DISEASE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; LAMINA PROPRIA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0037378345     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00450.2002     Document Type: Article

References (48)

1. Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A, Nohara C, Yagita H, and Okumura K. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol 162: 7058-7066, 1999.
2. Al-Shamkhani A, Birkeland ML, Puklavee M, Brown MH, James W, and Barelay AN. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for OX40 ligand. Eur J Immunol 26: 1695-1699, 1996.
3. Brugnoni D, Bettinardi A, Malacarne F, Airo P, and Cattaneo R. CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis. Br J Rheumatol 37: 584-585, 1998.
4. Chambers CA. The expanding world of co-stimulation: the two-signal model revised. Trends Biochem Sci 22: 217-223, 2001.
5. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML, Greengield EA, Baum PR, Fanslow WC, Calderhead DM, Freeman GJ, and Sharp AH. OX40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity 11:689-698, 1999.
6. Coyle AJ and Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immun 2: 203-209, 2001.
7. De Benedette MA, Shahinian A, Mak TW, and Watte TH. Costimulation of CD28+ T lymphocytes by 4-1BB ligand. J Immunol 158: 551-559, 1997.
8. De Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, Bhan AK, and Terhorst C. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 119: 715-723, 2000.
9. Fiocchi C. Inflammatory bowel disease-ethiology and pathogenesis. Gastroenterology 115: 182-205, 1998.
10. Godfrey WR, Fagnoni FF, Harara MA, Buck D, and Engleman EG. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 180: 757-762, 1994.
11. Gramaglia I, Weinberg AD, Lemon M, and Croft M. OX40 ligand: a potent costimulatory molecule for sustaining primary CD4 T-cell responses. J Immunol 161: 6510-6517, 1998.
12. Grewal IS and Flavell RA. A central role of CD40 ligand in the regulation of CD4+ T cell response. Immunol Today 17: 410-414, 1996.
13. Higgins LM, McDonald SAC, Whittle N, Crockett N, Shields JG, and MacDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with with an OX40 ligand-IgG fusion protein. J Immunol 162: 486-493, 1999.
14. Hurtade JC, Kim SH, Pollok KE, Lee ZH, and Kwon BS. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 155: 3360-3367, 1995.
15. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, Imamura S, and Uchiyama T. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 183: 2185-2195, 1996.
16. June CH, Bluestone JA, Nadler LM, and Thompson CB. The B7 and CD28 receptor families. Immunol Today 15: 321-331, 1994.
17. Kawachi S, Morise Z, Iennings SR, Conner E, Cockrell A, Laroux FS, Chervenak RP, Wolcott M, van der Heyde H, Gray L, Feng L, Granger DN, Specian RA, and Grisham MB. Cytokine and adhesion molecule expression in SCID mice reconstituted with CD4+ T cells. Inflamm Bowel Dis 6: 171-180, 2000.
18. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, and Hancock WW. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spare Th2 cytokines in the central nervous system. J Immunol 155: 4521-4524, 1995.
19. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathogies. Immunity 10: 387-398, 1999.
20. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, Ecabert B, Odermatt B, and Bachmann MF. OX40-deficient mice are defective in Th1 cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11: 699-708, 1999.
21. Kuchroo VK, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, and Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the, Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 80: 707-718, 1995.
22. high CD4+ T cells by blocking the CD40-CD154 interactions. J Immunol 164: 6005-6014, 2000.
23. Lynch DH, Ramsdell F, and Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 16: 569-574, 1995.
24. Mallett S, Fossum S, and Barelay N. Characterization of the MRC OX 40 antigen of activated CD4 positive T lymphocytes: a molecule related to nerve growth factor receptor. EMBO J 9: 1063-1069, 1990.
25. Malmstrom V, Shipton D, Singh B, Al-Shamkhani A, Puklavee MJ, Barclay AN, and Powrie F. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 166: 6972-6981, 2001.
26. Matsumura Y, Imura A, Hori T, Uchiyama T, and Imamura S. Localization of OX40/gp34 in inflammatory skin diseases: a clue to elucidate the interaction between activated T cells and endothelial cells in infiltration. Arch Dermatol Res 289: 653-656, 1997.
27. Mauri C, Williams RO, Walmsley M, and Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 26:1511-1518, 1996.
28. Miossec P and Van Der Heiden W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 40: 2105-2115, 1997.
29. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, Noda T, and Sugamura K. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 191: 365-374, 2000.
30. Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, Ishii H, Azuma M, and Hibi T. Functional expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa. Gastroenterology 117: 536-543, 1999.
31. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambouos S, Meyer zum Buschenfelde KH, Strober W, and Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27: 1743-1750, 1997.
32. Nicholson LB and Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 8: 837-842, 1996.
33. Nohara C, Akiba H, Nakajima A, Inoue A, Koh CS, Ohshima H, Yagita H, Mizuno Y, and Okumura K. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathologic T cells. J Immunol 166: 2108-2115, 2001.
34. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski, and Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol 159: 3838-3848, 1997.
35. Pipping SD, Pana-Rossi C, Long J, Godfrey WR, Fowell DJ, Reiner SL, Birkeland ML, Locksley RM, Barclay AN, and Killen N. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 163: 6520-6529, 1999.
36. Podolsky DK. Inflammatory bowel disease. N Engl J Med 325: 928-937, 1995.
37. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic role. Immunity 3: 171-174, 1995.
38. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, Shevach EM, and Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180: 1961-1966, 1994.
39. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, and Mak TW. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261: 609-612, 1993.
40. Smith CA, Farrah T, and Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and cell death. Cell 76: 959-962, 1994.
41. Souza HS, Elia CCS, Spencer J, and MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, a4b7/ MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 45: 856-863. 1999.
42. Stuber E and Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral mmune response. J Exp Med 183: 979-989, 1996.
43. Stuber F, Strober W, and Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 183: 693-698, 1996.
44. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, Dewoody KL, Schaible TF, and Rutgeerts PJ. A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor a for Crohn's disease. N Engl J Med 337: 1029-1035, 1997.
45. Tittle TV, Weinberg AD, Steinkeler CN, and Maziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 89: 4652-4658, 1997.
46. Van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jasen J, Tytgat GNJ, and Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135, 1995.
47. Weinberg AD, Lemon M, Jones AJ, Vainiene M, Celnik B, Buenafe AC, Culbertson N, Bakke A, Vandenbark AA, and Offner H. OX40 antibody enhances for autoantigen specific Vβ8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J Neurosci Res 43: 42-49, 1996.
48. Yamamoto M, Yoshizaki K, Kishimoto T, and Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878-4882, 2000.